Company: SHPH
Filing Date: 2025-03-31
Form Type: DEF 14A
Source: 0001641172-25-001889
Chunk: 0

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-03-31
Form: DEF 14A
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

(Rule 14a - 101)

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934</div>

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

| ☐ | Preliminary                                                         
 Proxy Statement                                                     |
| ☐ | Confidential,                                                       
 for Use of the Commission Only (as permitted by Rule 14a - 6(e)(2)) |
| ☒ | Definitive                                                          
 Proxy Statement                                                     |
| ☐ | Definitive                                                          
 Additional Materials                                                |
| ☐ | Soliciting                                                          
 Material Pursuant to §240.14a - 12                                  |

<div align='center'>SHUTTLE PHARMACEUTICALS HOLDINGS, INC.

(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)</div>

Payment of Filing Fee (Check all boxes that apply):

| ☒ | No                                                                                              
 fee required                                                                                    |
| ☐ | Fee                                                                                             
 paid previously with preliminary materials                                                      |
| ☐ | Fee                                                                                             
 computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a–6(i)(1) and 0–11 |

<div align='center'>SHUTTLE PHARMACEUTICALS HOLdIngS, InC.</div>

2025 Annual Meeting of Stockholders

March 31, 2025

Dear Shareholders,

It is with great excitement
that I write to review the key milestones that have been reached over the past year and those that remain in focus to advance Shuttle
Pharma’s mission to improve outcomes for cancer patients receiving radiation therapy (RT).

LEAD PROGRAM LAUNCHED WITH ENROLLMENT MEETING ALL EXPECTATIONS

The biggest milestone achieved this past year was the successful launch of our Phase 2 trial of Ropidoxuridine and RT for treatment
of patients with glioblastoma. We officially reached that milestone in November 2024 when the first patients had been enrolled and treated
at three of the six cancer center affiliates: UVA Cancer Center, Miami Cancer Institute, part of Baptist Health South Florida, and the
John Theurer Cancer Center at Hackensack University Medical Center.

Since